Tremfya – also known as guselkumab – has been recommended by the National Institute for Health and Care Excellence (NICE) for people with active psoriatic arthritis whose disease does not respond to conventional disease-modifying anti-rheumatic drugs (DMARDs).
The group involves individuals who have had at least one biological DMARD or whose tumour necrosis factor inhibitors are contraindicated. The treatment, which has been developed by Janssen, can be taken alone or in combination with methotrexate…
